newsfilter
← Latest News
PR Newswire·

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies In connection with the transaction, Fusion announces $60.0 million private placement